Learn More
OBJECTIVES To determine the safety, tolerability and signs of efficacy of MOR103, a human monoclonal antibody to granulocyte-macrophage colony-stimulating factor (GM-CSF), in patients with rheumatoid(More)
BackgroundClinical activity of ankylosing spondylitis (AS) predicts the natural course of the disease and the response to treatment. Several molecules are involved in new bone formation resulting in(More)
Human blood monocytes are divided into 3 subsets: classical (CD14 CD16 ), intermediate (CD14 CD16 ), and nonclassical (CD14 CD16 ).1 The latter 2 subpopulations produce inflammatory cytokines in(More)